Use of non-cryopreserved peripheral blood stem cells (PBSC) is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant
The current standard of care for transplant eligible patients with multiple myeloma is 4-6 cycles of induction therapy with three drugs which induces response in 80 to 90% patients, followed by autologous stem cell transplantation.1
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Uday Kulkarni, Anup J Devasia, Anu Korula, Fouzia NA, Nisham PN, Yasir J Samoon, Kavitha M Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George Source Type: research